Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
0.2070
-0.0222 (-9.69%)
At close: Mar 16, 2026, 4:00 PM EDT
0.2370
+0.0300 (14.49%)
After-hours: Mar 16, 2026, 6:54 PM EDT
Akari Therapeutics, Employees
As of December 31, 2024, Akari Therapeutics, had 9 total employees, including 8 full-time and 1 part-time employees. The number of employees decreased by 3 or -25.00% compared to the previous year.
Employees
9
Change (1Y)
-3
Growth (1Y)
-25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,752,444
Market Cap
7.40M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 9 | -3 | -25.00% | 8 | 1 |
| Dec 31, 2023 | 12 | -3 | -20.00% | 9 | 3 |
| Dec 31, 2022 | 15 | 6 | 66.67% | 15 | 0 |
| Dec 31, 2021 | 9 | 0 | - | 9 | 0 |
| Dec 31, 2020 | 9 | -1 | -10.00% | 9 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 117 |
| CollPlant Biotechnologies | 57 |
| Cardio Diagnostics Holdings | 15 |
| Dogwood Therapeutics | 12 |
| Kiora Pharmaceuticals | 12 |
| Processa Pharmaceuticals | 10 |
| PharmaCyte Biotech | 2 |
| SciSparc | 2 |
AKTX News
- 3 days ago - Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala - GlobeNewsWire
- 18 days ago - Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board - GlobeNewsWire
- 26 days ago - Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference - GlobeNewsWire
- 4 weeks ago - Akari Therapeutics, Plc (AKTX) Discusses New Patent Filing and Expansion of ADC Pipeline for Solid Tumors Transcript - Seeking Alpha
- 4 weeks ago - Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company's Expanded ADC Pipeline - GlobeNewsWire
- 5 weeks ago - Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - GlobeNewsWire
- 7 weeks ago - Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors - GlobeNewsWire
- 2 months ago - Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026 - GlobeNewsWire